Genetics of nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1026-1037

  Dongiovanni, Paola ^a   Valenti, Luca ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Genetics; Lipid metabolism; Liver disease; Non alcoholic fatty liver disease; Steatohepatitis

Indexed keywords

CELL NUCLEUS RECEPTOR; FAT DROPLET; FATTY ACID; GLUCOKINASE; GLUCOKINASE REGULATOR; MEMBRANE PROTEIN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 PROTEIN; PHOSPHOLIPASE; REGULATOR PROTEIN; TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; FIBROGENESIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; HERITABILITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN SECRETION; LIVER DISEASE; MITOCHONDRION; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SENESCENCE; GENETIC PREDISPOSITION; GENOTYPE; LIVER; MUTATION; PATHOLOGY; PHYSIOLOGY;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPID METABOLISM; LIPOGENESIS; LIVER; MUTATION; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84945321040     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.08.018     Document Type: Article

References (151)

1. [1] Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
2. [2] Day, C.P., From fat to inflammation. Gastroenterology 130 (2006), 207–210.
3. [3] Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002), 134–140.
4. [4] Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
5. [5] Dongiovanni, P., Anstee, Q.M., Valenti, L., Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 19 (2013), 5219–5238.
6. [6] Cohen, J.C., Horton, J.D., Hobbs, H.H., Human fatty liver disease: old questions and new insights. Science 332 (2011), 1519–1523.
7. [7] Fabbrini, E., Mohammed, B.S., Magkos, F., Korenblat, K.M., Patterson, B.W., Klein, S., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134 (2008), 424–431.
8. [8] Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X.X., Pandey, S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 (2007), 1366–1374.
9. [9] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 (2005), 1343–1351.
10. [10] Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 (2005), 634–642.
11. [11] Korenblat, K.M., Fabbrini, E., Mohammed, B.S., Klein, S., Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134 (2008), 1369–1375.
12. [12] Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
13. [13] Mashek, D.G., Khan, S.A., Sathyanarayan, A., Ploeger, J.M., Franklin, M.P., Hepatic lipid droplet biology: getting to the root of fatty liver. Hepatology 62 (2015), 964–967.
14. [14] Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits"?. Gastroenterology 114 (1998), 842–845.
15. [15] Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (2010), 1836–1846.
16. [16] Valenti, L., Fracanzani, A.L., Fargion, S., The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. Semin Immunopathol 31 (2009), 359–369.
17. [17] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (2009), 1877–1887.
18. [18] Marra, F., Bertolani, C., Adipokines in liver diseases. Hepatology 50 (2009), 957–969.
19. [19] Lee, U.E., Friedman, S.L., Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25 (2011), 195–206.
20. [20] Schwimmer, J.B., Celedon, M.A., Lavine, J.E., Salem, R., Campbell, N., Schork, N.J., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136 (2009), 1585–1592.
21. [21] Guerrero, R., Vega, G.L., Grundy, S.M., Browning, J.D., Ethnic differences in hepatic steatosis: an insulin resistance paradox?. Hepatology 49 (2009), 791–801.
22. [22] Willner, I.R., Waters, B., Patil, S.R., Reuben, A., Morelli, J., Riely, C.A., Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96 (2001), 2957–2961.
23. [23] Minamiyama, Y., Takemura, S., Kodai, S., Shinkawa, H., Tsukioka, T., Ichikawa, H., et al. Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab 298 (2010), E1140–E1149.
24. [24] Kirsch, R., Sijtsema, H.P., Tlali, M., Marais, A.D., Hall, Pde L., Effects of iron overload in a rat nutritional model of non-alcoholic fatty liver disease. Liver Int 26 (2006), 1258–1267.
25. [25] Feldstein, A.E., Canbay, A., Angulo, P., Taniai, M., Burgart, L.J., Lindor, K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003), 437–443.
26. [26] Makkonen, J., Pietilainen, K.H., Rissanen, A., Kaprio, J., Yki-Jarvinen, H., Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 50 (2009), 1035–1042.
27. [27] Takehara, T., Tatsumi, T., Suzuki, T., Rucker, E.B. III, Hennighausen, L., Jinushi, M., et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127 (2004), 1189–1197.
28. [28] Loomba, R., Rao, F., Zhang, L., Khandrika, S., Ziegler, M.G., Brenner, D.A., et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 139 (2010), 836–845 [45 e1].
29. [29] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
30. [30] Dongiovanni, P., Donati, B., Fares, R., Lombardi, R., Mancina, R.M., Romeo, S., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 19 (2013), 6969–6978.
31. [31] Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B.G., Zhou, H.H., Tybjaerg-Hansen, A., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46 (2014), 352–356.
32. [32] Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A.L., Pipitone, R., Mozzi, E., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61 (2015), 506–514.
33. [33] Huang, Y., He, S., Li, J.Z., Seo, Y.K., Osborne, T.F., Cohen, J.C., et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 107 (2010), 7892–7897.
34. [34] He, S., McPhaul, C., Li, J.Z., Garuti, R., Kinch, L.N., Grishin, N.V., et al. A sequence variation (I148M) in PNPlA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285 (2009), 6706–6715.
35. [35] Pingitore, P., Pirazzi, C., Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 1481 (2014), 574–580.
36. [36] Pirazzi, C., Valenti, L., Motta, B.M., Pingitore, P., Hedfalk, K., Mancina, R.M., et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 23 (2014), 4077–4085.
37. [37] Ruhanen, H., Perttila, J., Holtta-Vuori, M., Zhou, Y., Yki-Jarvinen, H., Ikonen, E., et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 55 (2014), 739–746.
38. [38] He, S., McPhaul, C., Li, J.Z., Garuti, R., Kinch, L., Grishin, N.V., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285 (2010), 6706–6715.
39. [39] Pirazzi, C., Adiels, M., Burza, M.A., Mancina, R.M., Levin, M., Stahlman, M., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 57 (2012), 1257–1262.
40. [40] Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K.M., Gromada, J., et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61 (2014), 108–118.
41. [41] Fargion, S., Valenti, L., Dongiovanni, P., Fracanzani, A.L., TNFalpha promoter polymorphisms. Methods Mol Med 98 (2004), 47–58.
42. [42] Mancina, R.M., Matikainen, N., Maglio, C., Soderlund, S., Lundbom, N., Hakkarainen, A., et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J Clin Endocrinol Metab 100 (2015), E821–E825.
43. [43] Kotronen, A., Johansson, L.E., Johansson, L.M., Roos, C., Westerbacka, J., Hamsten, A., et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52 (2009), 1056–1060.
44. [44] Kollerits, B., Coassin, S., Beckmann, N.D., Teumer, A., Kiechl, S., Doring, A., et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genet 18 (2009), 4669–4676.
45. [45] Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Konigsrainer, I., et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58 (2009), 2616–2623.
46. [46] Rotman, Y., Koh, C., Zmuda, J.M., Kleiner, D.E., Liang, T.J., The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52 (2010), 894–903.
47. [47] Speliotes, E.K., Butler, J.L., Palmer, C.D., Voight, B.F., Hirschhorn, J.N., PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52 (2010), 904–912.
48. [48] Valenti, L., Al-Serri, A., Daly, A.K., Galmozzi, E., Rametta, R., Dongiovanni, P., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1209–1217.
49. [49] Sookoian, S., Pirola, C.J., Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53 (2011), 1883–1894.
50. [50] Romeo, S., Sentinelli, F., Cambuli, V.M., Incani, M., Congiu, T., Matta, V., et al. The 148 M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 53 (2010), 335–338.
51. [51] Santoro, N., Kursawe, R., D'Adamo, E., Dykas, D.J., Zhang, C.K., Bale, A.E., et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52 (2010), 1182–1189.
52. [52] Valenti, L., Alisi, A., Galmozzi, E., Bartuli, A., Del Menico, B., Alterio, A., et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52 (2010), 1274–1280.
53. [53] Viitasalo, A., Pihlajamaki, J., Lindi, V., Atalay, M., Kaminska, D., Joro, R., et al. Associations of I148M variant in PNPLA3 gene with plasma ALT levels during 2-year follow-up in normal weight and overweight children: the PANIC Study. Pediatr Obes 10 (2014), 84–90.
54. [54] Romeo, S., Sentinelli, F., Dash, S., Yeo, G.S., Savage, D.B., Leonetti, F., et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 34 (2009), 190–194.
55. [55] Miraglia Del Giudice, E., Grandone, A., Cirillo, G., Santoro, N., Amato, A., Brienza, C., et al. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One, 6, 2011, e27933.
56. [56] Graff, M., North, K.E., Franceschini, N., Reiner, A.P., Feitosa, M., Carr, J.J., et al. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI Family Heart Study. Int J Obes (Lond) 37 (2012), 432–438.
57. [57] Valenti, L., Rumi, M., Galmozzi, E., Aghemo, A., Del Menico, B., De Nicola, S., et al. Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53 (2011), 791–799.
58. [58] Vigano, M., Valenti, L., Lampertico, P., Facchetti, F., Motta, B.M., D'Ambrosio, R., et al. PNPLA3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 58 (2013), 1245–1252.
59. [59] Valenti, L., Maggioni, P., Piperno, A., Rametta, R., Pelucchi, S., Mariani, R., et al. PNPLA3 I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol 18 (2012), 2813–2820.
60. [60] Stattermayer, A.F., Traussnigg, S., Dienes, H.P., Aigner, E., Stauber, R., Lackner, K., et al. Hepatic steatosis in Wilson disease — role of copper and PNPLA3 mutations. J Hepatol 63 (2015), 156–163.
61. [61] Tian, C., Stokowski, R.P., Kershenobich, D., Ballinger, D.G., Hinds, D.A., Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42 (2009), 21–23.
62. [62] Davis, J.N., Le, K.A., Walker, R.W., Vikman, S., Spruijt-Metz, D., Weigensberg, M.J., et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 92 (2011), 1522–1527.
63. [63] Nobili, V., Liccardo, D., Bedogni, G., Salvatori, G., Gnani, D., Bersani, I., et al. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes Nutr, 9, 2014, 392.
64. [64] Sevastianova, K., Santos, A., Kotronen, A., Hakkarainen, A., Makkonen, J., Silander, K., et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 96 (2012), 727–734.
65. [65] Santoro, N., Savoye, M., Kim, G., Marotto, K., Shaw, M.M., Pierpont, B., et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One, 7, 2012, e37827.
66. [66] Nobili, V., Bedogni, G., Donati, B., Alisi, A., Valenti, L., The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 16 (2013), 957–960.
67. [67] Valenti, L., Rumi, M., Galmozzi, E., Aghemo, A., Del Menico, B., De Nicola, S., et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53 (2011), 791–799.
68. [68] Valenti, L., Aghemo, A., Stattermayer, A.F., Maggioni, P., De Nicola, S., Motta, B.M., et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 35 (2012), 1434–1442.
69. [69] Valenti, L., Colombo, M., Fargion, S., Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. J Hepatol 55 (2011), 1470–1471 [author reply 1–2].
70. [70] Trepo, E., Guyot, E., Ganne-Carrie, N., Degre, D., Gustot, T., Franchimont, D., et al. PNPLA3 (rs738409 C > G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 55 (2012), 1307–1308.
71. [71] Valenti, L., Dongiovanni, P., Ginanni Corradini, S., Burza, M.A., Romeo, S., PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis 45 (2013), 619–624.
72. [72] Trepo, E., Nahon, P., Bontempi, G., Valenti, L., Falleti, E., Nischalke, H.D., et al. Association between the PNPLA3 (rs738409 C > G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 59 (2014), 2170–2177.
73. [73] Valenti, L., Al-Serri, A., Daly, A.K., Galmozzi, E., Rametta, R., Dongiovanni, P., et al. Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1209–1217.
74. [74] Valenti, L., Alisi, A., Nobili, V., I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. Hepatology 56 (2012), 1883–1889.
75. [75] Valenti, L., Alisi, A., Galmozzi, E., Bartuli, A., Del Menico, B., Alterio, A., et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52 (2010), 1274–1280.
76. [76] Mondul, A., Mancina, R.M., Merlo, A., Dongiovanni, P., Rametta, R., Montalcini, T., et al. PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity. J Nutr 145 (2015), 1687–1691.
77. [77] Hyysalo, J., Gopalacharyulu, P., Bian, H., Hyotylainen, T., Leivonen, M., Jaser, N., et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 63 (2013), 312–322.
78. [78] Sookoian, S., Castano, G.O., Burgueno, A.L., Gianotti, T.F., Rosselli, M.S., Pirola, C.J., A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 50 (2009), 2111–2116.
79. [79] Liu, Y.L., Patman, G., Leathart, J., Burt, A., Day, C., Daly, A., et al. Carriage of PNPLA3 I148M is associated with increased risk of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol, 58, 2013, S516.
80. [80] Hyysalo, J., Mannisto, V.T., Zhou, Y., Arola, J., Karja, V., Leivonen, M., et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60 (2014), 839–846.
81. [81] Nobili, V., Donati, B., Panera, N., Vongsakulyanon, A., Alisi, A., Dallapiccola, B., et al. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 58 (2014), 632–636.
82. [82] Scorletti, E., West, A.L., Bhatia, L., Hoile, S.P., McCormick, K.G., Burdge, G.C., et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol, 2015 [in press].
83. [83] Dongiovanni, P., Petta, S., Mannisto, V., Margherita Mancina, R., Pipitone, R., Karja, V., et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 63 (2015), 705–712.
84. [84] Sevastianova, K., Kotronen, A., Gastaldelli, A., Perttila, J., Hakkarainen, A., Lundbom, J., et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 94 (2011), 104–111.
85. [85] Morita, T., Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005), 1786–1795.
86. [86] Speliotes, E.K., Yerges-Armstrong, L.M., Wu, J., Hernaez, R., Kim, L.J., Palmer, C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet, 7, 2011, e1001324.
87. [87] Albert, J.S., Yerges-Armstrong, L.M., Horenstein, R.B., Pollin, T.I., Sreenivasan, U.T., Chai, S., et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med 370 (2014), 2307–2315.
88. [88] Fischer, J., Lefevre, C., Morava, E., Mussini, J.M., Laforet, P., Negre-Salvayre, A., et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 39 (2007), 28–30.
89. [89] Gandotra, S., Le Dour, C., Bottomley, W., Cervera, P., Giral, P., Reznik, Y., et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 364 (2011), 740–748.
90. [90] Garg, A., Acquired and inherited lipodystrophies. N Engl J Med 350 (2004), 1220–1234.
91. [91] Holmen, O.L., Zhang, H., Fan, Y., Hovelson, D.H., Schmidt, E.M., Zhou, W., et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 46 (2014), 345–351.
92. [92] Liu, Y.L., Reeves, H.L., Burt, A.D., Tiniakos, D., McPherson, S., Leathart, J.B., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun, 5, 2014, 4309.
93. [93] Chalasani, N., Wilson, L., Kleiner, D.E., Cummings, O.W., Brunt, E.M., Unalp, A., Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48 (2008), 829–834.
94. [94] Milano, M., Aghemo, A., Mancina, R.M., Fischer, J., Dongiovanni, P., De Nicola, S., et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology 62 (2015), 111–117.
95. [95] Kozlitina, J., Boerwinkle, E., Cohen, J.C., Hobbs, H.H., Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53 (2011), 467–474.
96. [96] Acton, B., Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 29 (2006), 2084–2089.
97. [97] Valenti, L., Nobili, V., Al-Serri, A., Rametta, R., Leathart, J.B., Zappa, M.A., et al. The APOC3 T-455C and C-482 T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 55 (2011), 1409–1414.
98. [98] Cefalu, A.B., Pirruccello, J.P., Noto, D., Gabriel, S., Valenti, V., Gupta, N., et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 33 (2013), 2021–2025.
99. [99] Di Filippo, M., Moulin, P., Roy, P., Samson-Bouma, M.E., Collardeau-Frachon, S., Chebel-Dumont, S., et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol 61 (2014), 891–902.
100. [100] Petta, S., Miele, L., Bugianesi, E., Camma, C., Rosso, C., Boccia, S., et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One, 9, 2014, e87523.
101. [101] Beer, N.L., Tribble, N.D., McCulloch, L.J., Roos, C., Johnson, P.R., Orho-Melander, M., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18 (2009), 4081–4088.
102. [102] Rametta, R., Mozzi, E., Dongiovanni, P., Motta, B.M., Milano, M., Roviaro, G., et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int J Obes 37 (2013), 986–992.
103. [103] Peter, A., Stefan, N., Cegan, A., Walenta, M., Wagner, S., Konigsrainer, A., et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96 (2011), E1126–E1130.
104. [104] Haeusler, R.A., Hartil, K., Vaitheesvaran, B., Arrieta-Cruz, I., Knight, C.M., Cook, J.R., et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun, 5, 2014, 5190.
105. [105] Santoro, N., Zhang, C.K., Zhao, H., Pakstis, A.J., Kim, G., Kursawe, R., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55 (2011), 781–789.
106. [106] Valenti, L., Alisi, A., Nobili, V., Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 55 (2012), 661–663.
107. [107] Hirsch, D., Stahl, A., Lodish, H.F., A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci U S A 95 (1998), 8625–8629.
108. [108] Hubbard, B., Doege, H., Punreddy, S., Wu, H., Huang, X., Kaushik, V.K., et al. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130 (2006), 1259–1269.
109. [109] Doege, H., Grimm, D., Falcon, A., Tsang, B., Storm, T.A., Xu, H., et al. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem 283 (2008), 22186–22192.
110. [110] Auinger, A., Valenti, L., Pfeuffer, M., Helwig, U., Herrmann, J., Fracanzani, A.L., et al. A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. Horm Metab Res 42 (2010), 854–859.
111. [111] Acton, R.T., Barton, J.C., Passmore, L.V., Adams, P.C., Speechley, M.R., Dawkins, F.W., et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 29 (2006), 2084–2089.
112. [112] Dongiovanni, P., Rametta, R., Fracanzani, A.L., Benedan, L., Borroni, V., Maggioni, P., et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol, 10, 2010, 102.
113. [113] Dongiovanni, P., Valenti, L., Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?. PPAR Res, 2013, 2013, 452061.
114. [114] Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
115. [115] Tonjes, A., Scholz, M., Loeffler, M., Stumvoll, M., Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29 (2006), 2489–2497.
116. [116] Kumari, M., Schoiswohl, G., Chitraju, C., Paar, M., Cornaciu, I., Rangrez, A.Y., et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 15 (2012), 691–702.
117. [117] Pollin, T.I., Damcott, C.M., Shen, H., Ott, S.H., Shelton, J., Horenstein, R.B., et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322 (2008), 1702–1705.
118. [118] Valenti, L., Motta, B.M., Alisi, A., Sartorelli, R., Buonaiuto, G., Dongiovanni, P., et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 54 (2012), 588–593.
119. [119] Caldwell, S.H., Swerdlow, R.H., Khan, E.M., Iezzoni, J.C., Hespenheide, E.E., Parks, J.K., et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31 (1999), 430–434.
120. [120] Berardi, M.J., Chou, J.J., Fatty acid flippase activity of UCP2 is essential for its proton transport in mitochondria. Cell Metab 20 (2014), 541–552.
121. [121] Fares, R., Petta, S., Lombardi, R., Grimaudo, S., Dongiovanni, P., Pipitone, R., et al. The UCP2–866 G > A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int 35 (2014), 1574–1580.
122. [122] Valenti, L., HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138 (2010), 905–912.
123. [123] Shimoda-Matsubayashi, S., Matsumine, H., Kobayashi, T., Nakagawa-Hattori, Y., Shimizu, Y., Mizuno, Y., Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 226 (1996), 561–565.
124. [124] Sutton, A., Khoury, H., Prip-Buus, C., Cepanec, C., Pessayre, D., Degoul, F., The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13 (2003), 145–157.
125. [125] Al-Serri, A., Anstee, Q.M., Valenti, L., Nobili, V., Leathart, J.B., Dongiovanni, P., et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 56 (2012), 448–454.
126. [126] Namikawa, C., Shu-Ping, Z., Vyselaar, J.R., Nozaki, Y., Nemoto, Y., Ono, M., et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 40 (2004), 781–786.
127. [127] Valenti, L., Fracanzani, A.L., Bugianesi, E., Dongiovanni, P., Galmozzi, E., Vanni, E., et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138 (2010), 905–912.
128. [128] Valenti, L., Canavesi, E., Galmozzi, E., Dongiovanni, P., Rametta, R., Maggioni, P., et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 53 (2010), 927–933.
129. [129] Valenti, L., Rametta, R., Dongiovanni, P., Motta, B.M., Canavesi, E., Pelusi, S., et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One, 7, 2012, e48804.
130. [130] Grarup, N., Urhammer, S.A., Ek, J., Albrechtsen, A., Glumer, C., Borch-Johnsen, K., et al. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia 49 (2006), 2097–2104.
131. [131] Dongiovanni, P., Valenti, L., Rametta, R., Daly, A.K., Nobili, V., Mozzi, E., et al. Genetic variants regulating Insulin Receptor signaling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease. Gut 59 (2010), 267–273.
132. [132] Anstee, Q.M., Darlay, R., Leathart, J.B., Clement, J., Clement, K., Aithal, G.P., et al. Genome-wide association analysis confirms importance of PNPLA3 and identifies novel variants associated with histologically progressive steatohepatitis in NAFLD. Hepatology 56 (2012), 265A–266A.
133. [133] Kitamoto, A., Kitamoto, T., Nakamura, T., Ogawa, Y., Yoneda, M., Hyogo, H., et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 61 (2014), 683–689.
134. [134] Ishizuka, Y., Nakayama, K., Ogawa, A., Makishima, S., Boonvisut, S., Hirao, A., et al. TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. J Mol Endocrinol 52 (2014), 145–158.
135. [135] Makishima, S., Boonvisut, S., Ishizuka, Y., Watanabe, K., Nakayama, K., Iwamoto, S., Sin3A-associated protein, 18 kDa, a novel binding partner of TRIB1, regulates MTTP expression. J Lipid Res 56 (2015), 1145–1152.
136. [136] Valenti, L., Fracanzani, A.L., Dongiovanni, P., Santorelli, G., Branchi, A., Taioli, E., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122 (2002), 274–280.
137. [137] Pastor, I.J., Laso, F.J., Romero, A., Gonzalez-Sarmiento, R., 238 G > A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res 29 (2005), 1928–1931.
138. [138] Gochee, P.A., Jonsson, J.R., Clouston, A.D., Pandeya, N., Purdie, D.M., Powell, E.E., Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol 18 (2003), 386–392.
139. [139] Petta, S., Grimaudo, S., Camma, C., Cabibi, D., Marco, V.D., Licata, G., et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 56 (2012), 1356–1362.
140. [140] Eslam, M., Hashem, A.M., Leung, R., Romero-Gomez, M., Berg, T., Dore, G.J., et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun, 6, 2015, 6422.
141. [141] Oh, D.Y., Talukdar, S., Bae, E.J., Imamura, T., Morinaga, H., Fan, W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142 (2010), 687–698.
142. [142] Valenti, L., Nobili, V., Deciphering the role of omega3 fatty acids in nonalcoholic steatohepatitis. J Pediatr Gastroenterol Nutr 59 (2014), 423–424.
143. [143] Marzuillo, P., Grandone, A., Conte, M., Capuano, F., Cirillo, G., Di Sessa, A., et al. Novel association between a non-synonymous variant (R270H) of the G protein-coupled receptor 120 and liver injury in obese children and adolescents. J Pediatr Gastroenterol Nutr 59 (2014), 472–475.
144. [144] Dongiovanni, P., Romeo, S., Valenti, L., Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 20 (2014), 12945–12955.
145. [145] Calado, R.T., Regal, J.A., Kleiner, D.E., Schrump, D.S., Peterson, N.R., Pons, V., et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One, 4, 2009, e7926.
146. [146] Hartmann, D., Srivastava, U., Thaler, M., Kleinhans, K.N., N'Kontchou, G., Scheffold, A., et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 53 (2011), 1608–1617.
147. [147] Aravinthan, A., Mells, G., Allison, M., Leathart, J., Kotronen, A., Yki-Jarvinen, H., et al. Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle 13 (2014), 1489–1494.
148. [148] Valenti, L., Dongiovanni, P., CDKN1A: a double-edged sword in fatty liver?. Cell Cycle 13 (2014), 1371–1372.
149. [149] Miele, L., Beale, G., Patman, G., Nobili, V., Leathart, J., Grieco, A., et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135 (2008), 282–291.
150. [150] Bechmann, L.P., Gastaldelli, A., Vetter, D., Patman, G.L., Pascoe, L., Hannivoort, R.A., et al. Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology 55 (2012), 1083–1093.
151. [151] Chalasani, N., Guo, X., Loomba, R., Goodarzi, M.O., Haritunians, T., Kwon, S., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139 (2010), 1567–1576 [76 e1-6].